NENCI, Giuseppe Giorgio
 Distribuzione geografica
Continente #
NA - Nord America 1.938
EU - Europa 1.535
AS - Asia 1.177
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 4.653
Nazione #
US - Stati Uniti d'America 1.922
HK - Hong Kong 664
UA - Ucraina 481
IE - Irlanda 327
SG - Singapore 263
SE - Svezia 152
FI - Finlandia 117
IT - Italia 117
DE - Germania 107
VN - Vietnam 89
RU - Federazione Russa 79
TR - Turchia 68
CN - Cina 67
GB - Regno Unito 52
FR - Francia 37
CA - Canada 16
BE - Belgio 14
CH - Svizzera 13
KR - Corea 9
PL - Polonia 9
NL - Olanda 8
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
GR - Grecia 5
AT - Austria 4
LB - Libano 4
BG - Bulgaria 3
LT - Lituania 3
EU - Europa 2
AM - Armenia 1
HU - Ungheria 1
ID - Indonesia 1
IN - India 1
IR - Iran 1
JP - Giappone 1
MY - Malesia 1
NO - Norvegia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 4.653
Città #
Hong Kong 664
Chandler 342
Dublin 327
Jacksonville 270
Singapore 218
San Mateo 201
Boardman 113
Dong Ket 88
Santa Clara 88
Medford 84
Princeton 84
Ann Arbor 79
Altamura 72
Izmir 68
Wilmington 64
Andover 48
Des Moines 48
Lawrence 43
Beijing 33
Helsinki 33
Saint Petersburg 23
Ashburn 22
Shanghai 18
Munich 15
Brussels 14
Los Angeles 13
Norwalk 13
Perugia 13
Ottawa 12
Woodbridge 12
New York 10
Seoul 9
Moscow 8
Dallas 7
Den Haag 7
Auburn Hills 6
San Paolo di Civitate 6
Houston 5
Dearborn 4
Kraków 4
London 3
Philadelphia 3
Sofia 3
Toronto 3
Capua 2
Casalbordino 2
Ciampino 2
Frankfurt am Main 2
Marsciano 2
Prague 2
Tappahannock 2
Biandronno 1
Cedar Rapids 1
Chicago 1
Edinburgh 1
Fano 1
Foligno 1
Hanoi 1
Hebei 1
Hyderabad 1
Imperial Beach 1
Johannesburg 1
Kiev 1
Kish 1
Kuala Lumpur 1
Langley 1
Lausanne 1
Leawood 1
Mountain View 1
New Castle 1
Olomouc 1
Oslo 1
Palermo 1
Paterson 1
Pekanbaru 1
Redwood City 1
Rome 1
San Francisco 1
Santa Maria 1
Sassari 1
Taipei 1
Vienna 1
Yerevan 1
Totale 3.246
Nome #
Fisiopatologia dell'emostasi 511
Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) 122
Activation of phospholipase A2 and B-thromboglobulin release in human platelets: comparative effects of thrombin and fluoroaluminate stimulation. 118
A case of Capnocytophaga canimorsus sepsis and suspected myocardial injury following a dog bite 98
LMWH or Ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials 79
Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism 78
Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma 78
OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial 77
Peripheral arteriopathy: effects of cloricromene on claudication and quality of life, a randomized double blind,,placebo controlled trial in patients treated with aspirin 77
Risk factor for upper limb deep vein thrombosis 76
Protein kinase C inhibitors enhance G-protein induced phospholipase A2 activation in intact human platelets 75
Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats 74
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. 71
Terapia anticoagulante orale con l’impiego di tecnologia POC e monitoraggio via web nell’ambito del Sistema Sanitario Nazionale Italiano 67
Activation of phospholipase A2 and ß-thromboglobulin release in human platelets stimulated with thrombin and fluoro aluminate 67
Intracellular signal transduction mechanisms regulating the release of lysosomes by activated human platelets 67
Effect of cloricromene on intermittent claudication. A randomized double-blind, placebo controlled trial in patients treated with aspirin: effect on claudication distance and quality of life 66
Kidney failure and endothelial disfunction: effects of haemodialysis 62
Effect of different plasma expanders on erythrocyte filterability 62
Prevalence of thrombophilic genetic mutations in patients undergoing thrombotic events while on oral anticoagulants a case-control study 60
Profilassi della trombosi venosa profonda in neurochirurgia 59
Effect of glyceryl trinitrate on distensibility of peripheral muscular arteries in humans is not mediated by prostaglandins 59
Cholinephosphotransferase activity in human platelet 58
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. 57
Characterization of N, N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. 56
Choline plasmalogen biosynthesis by transmethylation in human platelets 56
Differences between human platelets erythrocyte membranes.A spectroscopic study with particular refernce to IR and Laser Raman spectroscopy. 55
Effect of pentoxifylline on platelet aggregation 54
Assessment of occlusion of the vascular access in patients on chronic hemodialysis: comparison of physical examination with continuous-wave doppler ultrasound. 54
Evaluation of the antithrombotic activity of unfractioned heparin or nadroparine after oral administration in man 53
Erythocyte deformability changes in normal pregnancy and preeclampsia 53
Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial 53
Diagnostica generale delle malattie emorragiche. 53
Platelet activation and allergic asthma. 52
Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders 51
Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin -C treatment 51
Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism 50
Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression 50
Pharmacoeconomic evaluation of the management of oral anticoagulant treatment with point-of-care devices in the Italian national health care system 49
Eversion versus conventional carotid endarterectomy: late results of a prospective multicenter randomized trial 49
High shear stress induces nitric oxide synthesis in human platelets - 48
Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report 48
A randomized study on eversion versus standard carotid endarterectomy: Study design and preliminary results: The EVEREST Trial 48
Interaction beteween thrombophilic genetic mutations and clinical bleeding in patients undergoing chronic oral anticoagulant treatment 47
Protein kinase C inhibitors enhance G-protein induced phospholipase A2 activation in intact human platelets 47
Ultraviolet spectra of membrane-rich human platelet particulates. Normal data and specular abnormalities in hypo- and hyper-betalipoproteinemia 47
Risk factor for upper extremity deep vein thrombosis 46
Host-Drug Interaction: The Influence of Small Intestinal Bacterial Overgrowth on Oral Anticoagulant Dose Requirement 46
Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation 46
Vincristine-loaded platelets for autoimmune thrombocytopenic purpura 46
Red cell deformability alterations in normal late pregnancy: possible role of plasma components 46
Low molecular weight heparins prevent thrombin-induced thromboembolism in mice despite low antithrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. 44
Treatment of intermittent claudication with mesoglycan - a placebo-controlled, double - blind study. 44
Liquid Nitrogen Snap Frozen Saphenous Vein for Vascular Access in Dialysis 43
Human blood platelets release their lysosomal content ''in vivo'' at a localized site of platelet activation 43
Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor 42
Evidence for platelet activation in allergic asthma. 42
Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets. Role of adenylylcyclase up-regulation 41
Erythrocyte deformability in pre-eclamptic women and their newborn in the evaluation of microcirculatory impairment. 41
Thrombolytic therapy for thromboembolism of vertebrobasilar artery. 40
Evidence that cytosolic phospholipase A2 is down-regulated by protein kinase C in intact human platelets stimulated with fluoroaluminate. 40
Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. 39
Heparin and local haemostasis 39
The reduced erythrocyte deformability in pre-eclampsia is due to altered plasma to red blood cell interactions 39
Thrombolytic therapy for thromboembolism of the vertebrobasilar artery. 39
Intrinsically defective or exhausted platelets in hairy cell leukemia? 38
In vitro and ex vivo effect of indobufen on red blood cell deformability. 38
La safena omologa crioconservata come accesso dialitico: valutazione biologica e clinica 38
Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. 37
Interactions between platelets, other cells and eicosanoids in hypertension. 37
Platelets release their lysosomal content in vivo in humans upon activation 36
Infusion of vincristine-loaded platelets in acute ITP refractory to steroids: an alternative to splenectomy 36
Platelets and asthma 35
Platelet glycohydrolase activities: characterization and release 35
New pyridazinone derivatives as inhibitors of platelet aggregation. 34
Platelets release lambda-granules (lysosomes) in vivo in humans upon activation 34
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic diseases. 33
Vinca-loaded platelets 33
Ruolo del sistema emostatico nella patologia cardiovascolare. Generalità. 33
Treatment of intermittent claudication with medoglycan- a placebo-controlled, double-blind study 33
Intraoperative assessment of technical perfection in carotid endarterectomy: a prospective analysis of 1305 completion procedures 32
Thromboxane does not play a significant role in acute, cold induced vasoconstriction in raynaud’s phenomenon 30
Platelets release lambda-granules (lysosomes) “in vivo” in humans upon activation 24
Human blood platelets release their lysosomal content “in vivo” at a localised site of platelet activation 20
Platelet glycohydrolase activities: Characterization and release 2
Totale 4.786
Categoria #
all - tutte 19.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.112


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020244 0 0 0 0 0 9 71 17 75 32 7 33
2020/2021788 2 76 20 71 233 26 76 1 90 16 80 97
2021/2022641 9 117 18 27 20 2 6 234 5 16 71 116
2022/20231.149 96 195 26 84 83 140 0 51 417 1 34 22
2023/2024931 30 43 22 4 6 2 645 12 33 17 71 46
2024/2025449 9 150 24 26 210 30 0 0 0 0 0 0
Totale 4.786